1481
staff
Perry Wong
Perry Wong is managing director, China at the Milken Institute. He specializes in analyzing the s
tructure, industry mix, development, and public policies of a regional economy.
+ Read More
staff
Kevin Klowden
Kevin Klowden is the Executive Director of MI Finance at the Milken Institute.
staff
Kevin Hassett, PhD
Kevin Hassett, PhD, is managing director at the Milken Institute and the Brent R. Nicklas Disting
uished Fellow in Economics at the Hoover Institution at Stanford University.
+ Read More
staff
Ayodola Anise
Ayodola Anise is the senior director of operations working across FasterCures, Center for Public
Health, Center for the Future of Aging, and Feeding Change.
+ Read More
staff
David Talbot, PhD
David Talbot, PhD, is a director at the Milken Institute and leads research and policy programmin
g for the New Geo-Economics Initiative.
+ Read More
staff
Ilana Moreno
Ilana Moreno is a Senior Associate with Feeding Change at the Milken Institute.
staff
Holly Freishtat
Holly Freishtat is the senior director of Feeding Change at the Milken Institute.
staff
Katherine Sacks, PhD
Katherine Sacks is an Associate Director in health economics within the Research Department.
report
Global Opportunity Index 2022: White Paper
The Global Opportunity Index assesses countries' attractiveness to international investors using a
combination of economic, financial, institutional, and regulatory factors.
+ Read More
report
Global Opportunity Index 2022: Focus on Emerging Southeast Asia
This report uses the 2022 Global Opportunity Index (GOI) and its various categories to examine the
attractiveness of emerging Southeast Asia as a foreign investment destination—especially when compared to other emerging markets and developing economies
+ Read More
report
Achieving Health Equity: A Multi-Stakeholder Action Plan to Address Diversity across the Clinical Trials Enterprise and the Biomedical Research Ecosystem
Clinical trials have been used for decades as the primary way by which researchers determine if a n
ew treatment is safe and effective for human use.
+ Read More
report
COVID-19 Silver Linings for Biomedical Innovation: Implementation Roadmap
While the response to the COVID-19 pandemic has exposed many of the fault lines in the biomedical i
nnovation ecosystem that have slowed progress for decades, we have also shown ourselves capable of innovating in ways we perhaps did not think possible.
+ Read More